Sight Sciences (NASDAQ:SGHT - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.
SGHT has been the topic of several other reports. Lake Street Capital lifted their price target on Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a research report on Friday, May 9th. Piper Sandler reiterated a "neutral" rating and set a $4.00 price target (up from $3.50) on shares of Sight Sciences in a research report on Wednesday, June 18th. Stifel Nicolaus lowered their price target on Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Citigroup reiterated a "neutral" rating and set a $3.60 price target (up from $3.20) on shares of Sight Sciences in a research report on Thursday, May 22nd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $4.10.
Read Our Latest Research Report on SGHT
Sight Sciences Stock Performance
Shares of NASDAQ SGHT traded up $0.05 during mid-day trading on Friday, hitting $4.30. The company had a trading volume of 840,410 shares, compared to its average volume of 212,697. The stock has a market cap of $222.31 million, a price-to-earnings ratio of -4.39 and a beta of 2.46. Sight Sciences has a 12 month low of $2.03 and a 12 month high of $8.45. The company has a debt-to-equity ratio of 0.51, a current ratio of 10.47 and a quick ratio of 9.99. The firm's 50 day simple moving average is $3.60 and its two-hundred day simple moving average is $3.12.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. The business had revenue of $17.51 million for the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative return on equity of 54.62% and a negative net margin of 63.24%. As a group, equities research analysts forecast that Sight Sciences will post -0.99 earnings per share for the current year.
Insider Transactions at Sight Sciences
In related news, CEO Paul Badawi sold 24,174 shares of Sight Sciences stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the sale, the chief executive officer now owns 6,010,580 shares of the company's stock, valued at approximately $13,824,334. This trade represents a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 35,196 shares of company stock valued at $81,001 over the last quarter. Company insiders own 30.90% of the company's stock.
Institutional Trading of Sight Sciences
A number of institutional investors have recently bought and sold shares of SGHT. Long Focus Capital Management LLC boosted its position in Sight Sciences by 158.8% during the fourth quarter. Long Focus Capital Management LLC now owns 2,238,632 shares of the company's stock valued at $8,149,000 after purchasing an additional 1,373,535 shares during the last quarter. B Group Inc. acquired a new stake in Sight Sciences during the fourth quarter valued at $2,291,000. Prosight Management LP boosted its position in Sight Sciences by 71.1% during the fourth quarter. Prosight Management LP now owns 908,847 shares of the company's stock valued at $3,308,000 after purchasing an additional 377,625 shares during the last quarter. Renaissance Technologies LLC boosted its position in Sight Sciences by 654.3% during the fourth quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock valued at $1,431,000 after purchasing an additional 340,906 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in Sight Sciences by 127.7% during the first quarter. Acadian Asset Management LLC now owns 432,541 shares of the company's stock valued at $1,033,000 after purchasing an additional 242,559 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company's stock.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Recommended Stories
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
